68Ga vs. 18F in prostate cancer: Kesch and colleagues look at the clinical and logistic advantages of prostate-specific membrane antigen agents labeled with these 2 common tracers in patients with prostate cancer.
Page 687
PET, preclinical imaging, and optimal care: Clark and colleagues provide an overview of the underlying biochemical and biologic bases for a variety of PET tracers and discuss their potential in research to advance personalized cancer therapy.
Page 689
Prescribed activity of 131I: Van Nostrand offers commentary and perspective on the need for critical scrutiny of published evidence on selection of activity for 131I therapy in patients with well-differentiated thyroid cancer.
Page 697
Bevacizumab and 18F-FET uptake: Stegmayr and colleagues investigate the effects of bevacizumab on blood–brain barrier permeability and 18F-FET uptake on PET in a human xenograft model as a possible solution to confounding posttreatment pseudoresponses on MR imaging.
Page 700
Targeted imaging of micrometastases: Hekman and colleagues assess whether dual-modality imaging using a humanized anticarcinoembryonic antigen monoclonal antibody labeled with 111In-DTPA and a near-infrared fluorescent dye can detect pulmonary micrometastases in a mouse model.
Page 706
89Zr-bevacizumab PET in DIPGs: Jansen and colleagues determine the ability of bevacizumab to reach tumors in children with diffuse intrinsic pontine gliomas by measuring 89Zr-labeled bevacizumab uptake on PET, with additional data on safety and optimal imaging timing.
Page 711
RAI and metastatic thyroid cancer: Deandreis and colleagues compare empiric and whole-body/blood clearance dosimetry–based approaches to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer.
Page 717
Response prediction in esophageal cancer: Beukinga and colleagues report on a model designed to predict complete tumor response to neoadjuvant chemoradiotherapy in esophageal cancer based on pretreatment clinical parameters and 18F-FDG PET/CT–derived textural features.
Page 723
Predictive PET in HCC: Na and colleagues describe the prognostic value of 18F-FDG uptake on PET/CT at time of presentation in patients with Barcelona Clinic Liver Cancer stage C hepatocellular cancer.
Page 730
Follow-up PET/CT in oncology: Taghipour and colleagues explore retrospective data on common clinical indications for performing 4 or more follow-up 18F-FDG PET/CT scans and on resulting effects in patient management.
Page 737
Validation of Ki images: Ilan and colleagues evaluate parametric methods for computation of net influx rate in somatostatin analog imaging by comparison with volume-of-interest–based methods and assess image contrast in terms of tumor-to-liver ratio.
Page 744
Late PET/CT with 68Ga-PSMA-11: Afshar-Oromieh and colleagues assess effects on tumor detection and clinical impact of PET/CT imaging acquired 3 hours after injection of this small-molecule inhibitor of prostate-specific membrane antigen in patients with prostate cancer.
Page 750
SSTR PET/CT management: Barrio and colleagues detail the results of a systematic review and meta-analysis to evaluate the impact of somatostatin receptor PET/CT on management of patients with neuroendocrine tumors.
Page 756
Mapping A2AR with 11C-preladenant: Zhou and colleagues explore the suitability of 11C-preladenant PET imaging for quantification of striatal adenosine A2A receptors and assessment of receptor occupancy in conscious rhesus monkeys.
Page 762
Quantification of diaschisis: Segtnan and colleagues use 18F-FDG PET/CT to investigate the prognostic implications of total hemispheric glucose metabolism ratio in cerebrocerebellar diaschisis in patients with supratentorial gliomas.
Page 768
PET/CT and vulnerable plaques: Wan and colleagues quantify 68Ga-DOTATATE uptake in carotid plaque in patients with recent carotid events, assess inter- and intraobserver variability, and describe associated immunohistochemical markers.
Page 774
Sympathetic imaging in HFpEF: Boutagy and Sinusas offer perspective on the potential of radionuclide-based imaging of the cardiac sympathetic nervous system in patients with heart failure with preserved ejection fraction and preview a related article in this issue of JNM.
Page 781
11C-hydroxyephedrine PET in HFpEF: Aikawa and colleagues detail the relationship between myocardial sympathetic innervation quantified by 11C-hydroxyephedrine PET and diastolic dysfunction in patients with heart failure with preserved ejection fraction.
Page 784
Assessing cyclotron-produced 99mTc: Selivanova and colleagues report on a prospective clinical study with cyclotron-produced 99mTc-sodium pertechnetate in patients with indications for thyroid scanning to demonstrate safety and efficacy and to compare with conventional generator-eluted 99mTc-NaTcO4.
Page 791
Sympathetic innervation of BAT and WAT: Muzik and colleagues use 11C-HED, 15O-water, and 18F-FDG PET to explore the relationship between sympathetic innervation and cold-induced activation of brown and white adipose tissue in lean young adults.
Page 799
Optoacoustic tomography precision: Joseph and colleagues use phantoms and mice to assess the repeatability and reproducibility of a commercial small-animal optoacoustic tomography system and discuss the implications for reliable longitudinal imaging.
Page 807
2-18F-FEtOH as a perfusion reporter: Wadsworth and colleagues describe investigation of 2-18F-fluoroethanol PET in differentiation between tumors of varying perfusion levels, with potential applications in screening drugs that modify tumor perfusion.
Page 815
HER2-targeting peptide probe: Li and colleagues detail the development and preclinical evaluation of 99mTc-HYNIC-H6F, a human epidermal growth factor receptor 2–targeted peptide probe for SPECT imaging in breast cancer.
Page 821
11C-methoxybenzamide PET in melanoma: Garg and colleagues report on synthesis and preclinical assessment of this11C-labeled probe for selectively targeting melanoma using PET.
Page 827
4D MR and attenuation map generation: Fayad and colleagues investigate the generation of 4D MR images and associated attenuation maps from a single static MR image combined with motion fields obtained from simultaneously acquired 4D non–attenuation-corrected PET images.
Page 833
PET/MR implant AC: Fuin and colleagues present a novel technique for accurate whole-body attenuation correction in the presence of metallic endoprostheses on integrated non–time-of-flight PET/MR scanners.
Page 840
Motion correction for cardiac PET/MR: Kolbitsch and colleagues investigate a new cardiac PET/MR approach providing respiratory and cardiac motion-compensated MR and PET images in less than 5 minutes.
Page 846
In vivo hypoxia imaging in RA: Fuchs and colleagues measure hypoxia noninvasively in arthritic ankles with 18F-FMISO and 18F-FAZA PET/MR and quantify temporal and other dynamics of hypoxia and reactive oxygen species stress with a chemiluminescent optical imaging probe.
Page 853
- © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.